Ascentage Pharma presented data at the ASH Annual Meeting showcasing Lisaftoclax’s efficacy as a monotherapy for heavily pretreated BTK-refractory R/R CLL/SLL patients. The drug achieved a 62.5% objective response rate and a median progression-free survival of 23.89 months, with no reported tumor lysis syndrome. Lisaftoclax demonstrated durable efficacy and manageable safety in patients with complex karyotype and high-risk factors like del(17p)/TP53 mutation, offering hope for underserved patients. The drug, a Bcl-2 selective inhibitor, is currently in global Phase III studies for CLL/SLL, AML, and MDS, showing promising results for addressing unmet clinical needs. Lisaftoclax monotherapy has shown significant clinical efficacy and a manageable safety profile in patients with heavily treated BTK-refractory R/R CLL/SLL. The treatment achieved a 62.5% objective response rate (ORR) and a median progression-free survival of 23.89 months. In high-risk patients, 21.8% achieved minimal residual disease (MRD) negativity in peripheral blood. The treatment demonstrated a manageable safety profile with hematologic toxicities as the most common adverse events. Lisaftoclax is being considered as a potential new treatment option for these patients. However, Lisaftoclax, Olverembatinib, and APG-5918 are still under investigation and not yet FDA approved. Lisaftoclax monotherapy has shown strong clinical efficacy and safety in patients with heavily pretreated BTK-refractory R/R CLL/SLL. The drug achieved a 62.5% objective response rate and a median progression-free survival of 23.89 months. This highlights Lisaftoclax as a potential new treatment option for these patients, with nearly half of them having a complex karyotype. No cases of tumor lysis syndrome were reported during the study, further emphasizing the drug’s manageable safety profile.

Read more at GlobeNewswire.: Ascentage Pharma Presents Pivotal China Registrational